circadian clock comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-26. Numbers and descriptions here follow the published literature rather than marketing material.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Melanoma inhibitory activity protein 3 (MIA3), also known as transport and Golgi organization protein 1 (TANGO1), is a protein that in humans is encoded by the MIA3 gene on chromosome 1. It is ubiquitously expressed in many tissues and cell types. MIA3 localizes to the endoplasmic reticulum (ER) exit site, where it binds bulky cargo molecules such as collagens and creates mega transport carriers for the export of cargoes from the ER. This function suggests that it plays a role in assembly of extracellular matrix (ECM) and bone formation. MIA3 has been demonstrated to contribute to both tumor suppression and progression. The MIA3 gene also contains one of 27 loci associated with increased risk of coronary artery disease.. A TANGO1 like protein called TALI is expressed in liver and intestine and shown to be required for the export of bulky very Low density lipoproteins (VLDL) and chylomicrons. TANGO1 and TALI assemble into rings around COPII coats and this function is necessary for export of bulky cargoes. The discovery of TANGO1 and understanding its function has revealed that cargo export from the ER is not be vesicles but involves transient tunnels between the ER exit site and the next compartment of the secretory pathway. Biallelic Mutations in TANGO1 cause syndrome disease and complete loss of TANGO1 leads of defects in bone mineralization.
The Trails of Cold Steel arc follows Rean Schwarzer and Class VII, a specialized group of students attending Thors Military Academy in the Erebonian Empire. The first game, Trails of Cold Steel was released for the PlayStation 3 and PlayStation Vita in Japan in 2013. Trails of Cold Steel II is a direct continuation of the first game and was released for the PlayStation 3 and Vita in 2014. The third and fourth games, Trails of Cold Steel III and IV, follow Rean in his new role as an instructor of a new Class VII at a branch campus of Thors. Cold Steel III was released for the PlayStation 4 (PS4) in Japan in 2017, while Cold Steel IV was released in the following year. A fifth game, Trails into Reverie, was released in 2020 and acts as an epilogue to both the Crossbell and Erebonia arcs and follows Rean, Lloyd, and a masked character known as C. English versions of Cold Steel and Cold Steel II were released by Xseed Games in 2015 and 2016, respectively. NIS America released Cold Steel III in 2019, IV in 2020, and Trails into Reverie in 2023. A box set containing all five games was released in Japan for the PS4 in July 2022.
Although developing, telomerase inhibition within malignant cancer cells can theoretically be used as a potential treatment. Real-time reverse transcription polymerase chain reaction (RT-PCR) quantifying hTERT expression in various tumor samples verified this varying expression. Telomeres in non-cancerous human cells are generally longer than in cancer cells, and telomerase-inhibiting therapy aims to selectively suppress telomerase activity in cancer cells while preserving normal telomerase activity in non-tumor cells. Telomere-targeted treatments include oligonucleotides, nucleosides, small molecule inhibitors, and more. Various natural compounds have been identified as having telomerase inhibitory properties, such as oleic acid, a fatty acid found in vegetable and animal oils.
Additionally, they were able to tune the retention factor for the analytes through isocratic temperature gradient elution. Ideal elutions occurred at 35 °C, but decreasing the temperature to 10 °C or raising it to 50 °C caused faster elutions either way. This is a strong indication that electrostatic and hydrophobic interactions can be similarly affected by changes in temperature. The major advantages from applying these success of this study include stationary phase versatility and maintaining bioactivity of the analytes. Ayano et al. modified PNIPAAm with cationic N,N-dimethylaminopropylacrylamide (DMAPAAm) and hydrophobic BMA and grafted it onto silica beads to form IDB. They used pH changes to adjust the LCST. The effect of pH on the LCST is as follows, from a plateau value between pH 4.5 and pH 6.0, the LCST decreased up to pH 9 and below pH 4.5. This can be interpreted as requiring slightly basic or moderately acidic conditions, as the 4.5–6.0 pH region holds a maximum value of the LCST, an unfavorable condition. They used these properties to separate several non-steroidal anti-inflammatory drugs (NSAIDs). The analysis of acidic drugs (salicylic acid: BA; SA; MS; and As) was performed below pH 4.5. MS is hydrophobic only its retention time was affected by an increase in temperature on the column without a terminally modified anion-exchanger (IB column). However, with an anion-exchanger present, dissociated acidic drugs were retained longer at temperatures below LCST, and shorter at temperatures above LCST.
=== Plant === Plant serpins were amongst the first members of the superfamily that were identified. The serpin barley protein Z is highly abundant in barley grain, and one of the major protein components in beer. The genome of the model plant, Arabidopsis thaliana contain 18 serpin-like genes, although only 8 of these are full-length serpin sequences. Plant serpins are potent inhibitors of mammalian chymotrypsin-like serine proteases in vitro, the best-studied example being barley serpin Zx (BSZx), which is able to inhibit trypsin and chymotrypsin as well as several blood coagulation factors. However, close relatives of chymotrypsin-like serine proteases are absent in plants. The RCL of several serpins from wheat grain and rye contain poly-Q repeat sequences similar to those present in the prolamin storage proteins of the endosperm. It has therefore been suggested that plant serpins may function to inhibit proteases from insects or microbes that would otherwise digest grain storage proteins. In support of this hypothesis, specific plant serpins have been identified in the phloem sap of pumpkin (CmPS-1) and cucumber plants. Although an inverse correlation between up-regulation of CmPS-1 expression and aphid survival was observed, in vitro feeding experiments revealed that recombinant CmPS-1 did not appear to affect insect survival. Alternative roles and protease targets for plant serpins have been proposed.
Sources: en.wikipedia.org
== Career == In 1977, Bowman joined International Plasma Corporation of Hayward, California as chief financial officer and general manager of its analytical instrument division. International Plasma Corporation owned Durrum Instrument Corporation, an instrumentation company that had purchased exclusive rights to an emergent technology, Ion chromatography, from Dow Chemical Company. Initial research by Hamish Small and others at the Dow Physical Research Laboratory in Midland, Michigan suggested that inorganic ion analysis would be superior to commonly used wet chemical techniques, but Dow was not interested in pursuing the idea. Bowman became interested in the potential of ion chromatography (IC) while at International Plasma Corporation. In 1980, Smith-Kline acquired International Plasma Corporation. The IC division was spun off as a separate company, under the name Dionex Corporation, in a leveraged buyout (LBO) led by A. Blaine Bowman. Bowman became the president and CEO of the new company, which was incorporated in California in 1980. The company was reincorporated in Delaware in 1986. Dionex began to trade publicly as of 1982. Under Bowman's leadership, Dionex made important advances both scientifically and economically. The company directed up to nine percent of its revenues back into its ongoing research and development program.
=== Traditional === Rotheca myricoides is used in traditional medicine to manage diabetes in the lower eastern part of Kenya. This area is populated mostly by the Kamba community. They take this medicine daily by boiling and consuming the leaves. This species is also used to treat epilepsy, arthritis, typhoid, cough, eye problems, tonsillitis, rheumatism, gonorrhoea, cancer, malaria, dysmenorrhea, sterility, and impotence. In traditional medicine, European and African cultures used the bark of the species in its powdered form, and a teaspoon is used to treat snakebites. The Masai used the root bark for East Coast fever in cattle and diarrhea in their calves. The Haya and Shambala used Rotheca myricoides for dysmenorrhoea and cough, furunculosis and swellings that are associated with debility. In various African communities, the root of the plant is also used for chest pain, colds, gum bleeding indigestion, headaches, and bathing people with convulsions. In West Africa, the plant is used for analgesic and antipyretic purposes. In Asian countries, this species has been brewed as a tea to relieve swelling and pain.
=== Medications === Medications for PMOS include metformin and oral contraceptives. Metformin is a medication commonly used in type 2 diabetes, and is used frequently off-label in the management of PMOS. It is recommended for those with a BMI over 25 to treat insulin resistance and normalise lipid profiles, and can also be considered for the treatment of irregular periods in adolescents and for those with a BMI under 25. Metformin is associated with several side effects, including abdominal pain, metallic taste in the mouth, diarrhoea and vomiting. It can also be used to help women get pregnant, but it is not the most effective drug for it. Combined oral contraceptives (COCs) can be used to reduce the symptoms of hirsutism and regulate menstrual periods. They increase sex hormone binding globulin production, and reduce levels of androgens. A regular cycle reduces the risk of endometrial cancer. Contraceptive pills with only progestogens can be used to improve menstrual regularity, but not for symptoms of androgen excess. Antiandrogens such as finasteride and flutamide do not show advantages over COCs for treating hirsutism, but can be an option for people for whom COCs are contraindicated or who do not tolerate them. It may take six to twelve months for COCs to be effective for hirsutism. For the treatment of androgenic alopecia, a combination of antiandrogens and combined oral contraceptives can be tried, but it is difficult to treat. GLP-1 receptor agonists, such as liraglutide and semaglutide, may be more effective than metformin alone at metabolic improvements.
== AFL career == Myers is originally from Perth in the WAFL, he also attended Wesley College, Perth. He was drafted with the 6th overall selection in the 2007 national draft by Essendon. Myers, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. The suspension lead to speculation that Myers would exercise his rights as an unrestricted free agent and leave Essendon, but during the year he signed a three-year contract to remain with Essendon until the end of the 2019 season. Myers announced his retirement at the end of the 2019 season with an open letter to the fans.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.